Suven Pharmaceuticals (BOM:543064) Debt-to-Equity : N/A (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Suven Pharmaceuticals Debt-to-Equity?

Suven Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₹0 Mil. Suven Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₹0 Mil. Suven Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2024 was ₹0 Mil.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Suven Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

BOM:543064' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.06 Max: 0.22
Current: 0.02

During the past 6 years, the highest Debt-to-Equity Ratio of Suven Pharmaceuticals was 0.22. The lowest was 0.02. And the median was 0.06.

BOM:543064's Debt-to-Equity is ranked better than
91.69% of 818 companies
in the Drug Manufacturers industry
Industry Median: 0.27 vs BOM:543064: 0.02

Suven Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Suven Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Suven Pharmaceuticals Debt-to-Equity Chart

Suven Pharmaceuticals Annual Data

Trend

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Debt-to-Equity

Get a 7-Day Free Trial

0.22

0.12

0.06

0.04

0.03

Suven Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Equity	Get a 7-Day Free Trial															N/A	0.03	N/A	0.02	N/A

Competitive Comparison of Suven Pharmaceuticals's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Suven Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Suven Pharmaceuticals's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Suven Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Suven Pharmaceuticals's Debt-to-Equity falls into.

Save Embed

;

Save Embed

;

Suven Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Suven Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(437.608	+	212.356)	/	20506.634
	=	0.03

Suven Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	0
	=	N/A

Suven Pharmaceuticals (BOM:543064) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Suven Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Suven Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Suven Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Suven Pharmaceuticals Ltd (BOM:543064) » Definitions » Debt-to-Equity

Traded in Other Exchanges

SUVENPHAR:India

Address

No. 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIIC, Raidurg, Hyderabad, TG, IND, 500081

Website

https://www.suvenpharm.com

Suven Pharmaceuticals Ltd is involved in developing and manufacturing intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs under Contract Research and Manufacturing Services (CRAMS) for global pharmaceutical, biotechnology, and chemical companies. The company operates majorly in the Manufacturing (CRAMS) segment, which includes bulk drugs and intermediates under contract services. Its geographical segments include India, the USA, Europe, and the Rest of the World. The majority of the company's revenue comes from the Europe segment.

Suven Pharmaceuticals Headlines

No Headlines